Journal of Biochemistry International

7(1): 29-38, 2020
ISSN: 2454-4760



PHOSPHATIDYLINOSITOL 3-KINASE AS A BIOMARKER FOR BREAST CANCER: A REVIEW

MARVIS AYOOLA AROWOLO[1*], MUTIU A. ALABI[1] AND EMMANUEL AJANI[1]
[1]Kwara State University, Malete, Kwara State, Nigeria.

AUTHORS' CONTRIBUTIONS
This work was carried out in collaborations among all authors. Author M. A. Arowolo designed the study, managed the literature searches, wrote the protocol and wrote the first draft of the manuscript. Authors M. A. Alabi and EA proofread the manuscript. All authors read and approved the final manuscript.

Received: 01 December 2020
Accepted: 05 February 2021
Published: 10 February 2021

Review Article

ABSTRACT

Cancer is one of the major causes of death in the world and the second leading cause of death after cardiovascular disease; approximately 70% of deaths from cancer occur in low- and middle- income countries. Breast cancer is the most prevalent cancer and the common cause of cancer mortality worldwide. Modification in various cell signalling pathways promotes cell proliferation, progression and survival. Phosphoinositide 3-kinase (PI3K) pathway is an intracellular signalling pathway that has regulatory roles in cell survival, proliferation, and differentiation. Activation of PI3K pathway contributes to the development of tumour, PI3K is an attractive therapeutic direction in the treatment of cancer. Inhibition of PI3K signalling is effective in the treatment of several types of cancer. In this review, PI3K inhibitors in breast cancer and combination of therapeutics strategies in cancer, importance of PI3K in breast cancer and current clinical studies were addressed.

Keywords: PI3K; breast cancer; biomarker; therapy.

1. INTRODUCTION

The second leading cause of death in the globe after cardiovascular disease is cancer, roughly 70% of deaths occurring in the low and middle earning countries is related to cancers as argued by WHO [1]. Cancer is a collection of infection illustrated by uninhibited development and multiplication of irregular cells [2]. The maximum percentage of cancer types in women occurs in the breast, lungs, thyroid, rectum, bronchus, colon and uterine corpus respectively while in men, maximum percentage of cancer types ensue in the prostrate, urinary bladder, lungs, bronchus, colon and rectum correspondingly [3].

Cancer occurrence in the blood, brain related and lymph nodes respectively for children, it disturbs cellular relationship resulting in the degradation of essential genes, which is affective throughout the cell cycle leading to unequal spread. Chemical compounds display a distinct role in the formation of gene mutations as well as cancer cells, smoking including multiple cancer-causing chemical compounds contributing to lung cancer [4], environmental chemicals with cancer-causing properties disturb directly or indirectly on the cytoplasm and cell nucleus contributing to genetic conditions and gene mutations.

**Corresponding author: Email: arowolo.marvis@lmu.edu.ng;*

Cancer of the breast is extensively diagnosed and the second-largest source of cancer associated death amongst women in human [4]. Cancer of the breast is caused mainly by inherited gene mutations containing BRCA1 and BRCA2. Breast cancer is categorized into different subtypes depending on progesterone receptor (PR), HER2 receptor and estrogen receptor (ER) existence or absence. Breast cancer pathogenesis is related to the pathological activation of many signalling pathways, in particular the phosphoinositide 3-kinase (PI3K) pathway.

Biomarker is a biological molecule contained in blood, other body fluids or tissues as specified by the National Cancer Institute and is an indication of a regular or irregular cycle. Biomarkers are observable features of physiological or pathological conditions and are designed to aid variety of functions during development of drugs that include providing evidence of concept, early treatment identification of non-respondents, optimizing patient selection and facilitating optimal determination of biological dosage.

Biomarkers are also known as genomic markers such as epidermal growth factor receptors (EGFR) and protein markers such as prostate-specific antigens for the discovery of prostate cancer, kinase mutations in lung cancer cells which envisage reaction to EGFR kinase inhibitors [5]. The goal of approaches to drug development is to achieve maximum biological outcome on the target which translates into efficacy of therapies.

Phosphoinositide 3-kinases (PI3Ks), a lipid kinases family that incorporate signs from cytokines, other extracellular stimuli and growth factors. They react to hormones, diets, and indications of the environment and incorporate extracellular stimuli into intracellular signals which control various biological functions, comprising differentiation, metabolism, migration, survival and cell multiplying. PI3Ks are classified into three enzyme-kinetic and structural classes: class I, class II and class III.

Class I PI3Ks are aberrantly activated in breast cancer, comprise of PI3Kα, PI3Kβ, PI3Kγ and PI3Kδ [6]. Class II PI3Ks synthesize both phosphatidylinositol 3-phosphate (PI(3)P) and phosphatidylinositol 3.4-bisphosphate (PI(3,4)P2) in distinct cellular compartments, the distinct feature involves C-terminal C2 domain that lacks critical aspartic acid residues to organise binding of Ca^{2+}. Class II comprises of three catalytic isoforms; PI3K-C2α which plays a significant role in clathrin-mediated endocytosis and mitosis, PI3K-C2β which is activated via growth factors, similarly intricate migration of cell and signalling repression of mTOR and PI3K-C2γ which localizes on early endosomes, furthermore controls Akt activation, as well as storage of glycogen in the liver. Class III PI3Ks produce phosphatidylinositol 3-phosphate (PI(3)P) from phosphoinositides, exists as heterodimers of Vps34 and a regulatory subunit, it involves trafficking of proteins and vesicles primarily [7].

For breast cancer, a series of diverse pathways will deregulate the PI3K pathway. PIK3CA triggering mutations found in either the kinase or helical domains are existent in more than one-third of timely breast tumours. PI3K upstream activation is by binding a ligand or growth factor to its cognate growth factor receptor tyrosine kinases (RTKs) that comprise associates of the human epidermal growth factor receptor (HER) family and insulin-like growth factor 1 (IGF-1) receptor [8].

This review; addresses the importance of PI3K as a biomarker in cancer. The PI3K cancer pathway, the PI3K pathway inhibition and the combination of cancer therapeutic strategies will be addressed.

1.1 Phosphoinositde 3-Kinase (PI3K) Pathway

Phosphoinositide 3-Kinase (PI3K) is a type of plasma membrane-associated lipid kinases comprising three subunits: regulatory subunit p55, regulatory subunit p85 and catalytic subunit p110. PI3Ks, principal biochemical purpose is to phosphorylate the phosphoinositide 3-hydroxyl group [9]. Phosphorylation results in second messenger molecules being activated by subsequent signal transduction, setting in action a diversity of physiological cell metabolism and survival functions [10]. PI3K signalling is among the most significant intracellular pathways that control numerous process of the cell. In this signalling route, mutations are often seen in cancer, approximately 60% of tumours harbour alterations in genetics which can hyperactivate PI3K pathway are often seen in cancer, especially breast cancer. Activating PI3K pathway leads to tumour growth and to anticancer therapy resistance. PI3K pathway has shown to be abnormally regulated in virtually all human cancers including colorectal cancer, cancer of the breast and hematologic malignancies [8]. PI3K inhibitors comprise PI3K/mTOR inhibitors, isoforms-selective PI3K inhibitors and pan-PI3K inhibitors.

PI3K are usually activated by means of a diversity of extracellular stimuli including cytokines, growth factors and hormones to their membrane bound tyrosine kinase receptors. Activation of class IA PI3Ks is instigated once a growth factor or ligand

joins to its cognate receptor tyrosine kinase (RTK). These receptors comprise elements of the receptor of growth factor copied from platelets, human epidermal growth factor receptor family, insulin and insulin like growth factor 1 (IGF-1) receptor.

The enabled kinase catalyses phosphorylation of phosphatidylinositol-4,5-biphosphate (PI(4,5)P2) into phosphatidylinositol-3,4,5-triphosphate (PI(3,4,5)P3), a second messenger that binds and recruit a subsets of pleckstrin-homology (PH), FYVE, Phax (PX), C1,C2 or other downstream lipid-binding domains to the cell membrane and also play a role of a docking site for PI3K activation [6]. The phosphorylation of phosphatidylinositol-4,5-biphosphate (PI(4,5)P2) to phosphatidylinositol-3,4,5-triphosphate (PI(3,4,5)P3) results in Akt phosphorylation, a serine/threonine kinase which affects proliferation, continued existence and development of cancer cells.

Akt enhances cell growth as well as protein synthesis through mTOR activation through effects on the Rheb-GTP protein-activating intermediate tuberous sclerosis (TSC) ½ complex, a tumour suppressor and heterodimer of tuberin and harartin. mTOR, a PI3K downstream and Akt effector [6]. It consist of two diverse complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2), that are identical in structure and distinct functionally.

Phosphatase and tensin homologue delete on chromosome 10 (PTEN) control pathways via dephosphorylating PIP3 to PIP2 thereby, preventing downstream kinase activation [7]. The importance of abnormal PI3K signalling has been shown to occur in several diseases including various cancers, HIV and HVC infections in addition to autoimmunity. Regular activation of PI3K pathway in cancer, its vital role in the development of cell and continued existence has made it a considerable aim for pharmacological interventions.

1.2 Phosphoinositide 3-Kinase Pathway in Breast Cancer

PI3K is a cell signalling pathway that is concerned with the regulation of growth, motility, proliferation, immune response and metabolism [7]. PI3K pathway is thought to be deregulated in an extensive range of human cancers. Mutation of kinase or reduced PTEN expression results to conversion of neoplastic, underlining its central function in carcinogenesis among humans. PI3K pathway is the most commonly amplified cancer of the breast via various mechanism comprising: (i) over expressing signals activation, for instance, human epidermal growth factor receptor 2 (HER2); (ii) increase PI3K activities by mutation/amplification of PIK3CA, PIK3CB or PIK3R1; (iii) loss or inactivation of negative regulators for instance, PTEN and INPP4B or (iv) overexpressing downstream effectors AKT1, AKT2 or PDK [10].

PI3K inhibition direct effects on breast cancer cells are important, study indicates that inhibition of PI3K indirectly influences cancer of the breast cell by aiming the tumour microenvironment [11]. Activation of a cellular receptor leads to dimers and auto phosphorylation in different areas, in phosphorylation, diverse protein adapters which attach to certain phosphorylated residues and produces a conformational shift that discharge p110 [11]. A phosphate group is then added to phosphatidylinositol 4,5-bisphosphate (PIP2), that is then changed into phosphatidylinositol (3,4,5)-triphosphate (PIP3) [12]. The most significant negative regulator of the PI3K and one of the tumour suppressors with maximal consequence on cancer of diverse category is the Phosphatase and tensin homolog (PTEN) that has the ability to extract from PIP3 a phosphate and convert it to PIP2 [12]. PTEN functions as a straight opponent of PI3K action by means of PIP3 dephosphorylation. PTEN complexes dimers are more active in PIP3 dephosphoryation than PTEN monomers and PI3K signalling regulation.

PIK3CA, a gene encoding the subunit p110α, is often amplified or mutated in extreme mutual cancers in humans, such as cancer of the breast, cervical, lung, gastric and prostate cancer [13]. Mutations are important constituents of PIK3CA, activating PIK3CA mutations have been recognized as active oncogenic mechanisms involved in this pathway's hyperactivation; these mutations are specifically notable in cancer of the breast, with around 27% patients having this gene mutations [14]. Activation of PI3K is a key phase in oncogenesis and plays a part in resistance to treatment in ER/HER2+ breast cancers. There are inhibitors of PI3K previously used in clinical trials [15].

1.3 Phosphoinositide 3-Kinase Inhibitors in Breast Cancer

PI3K is assumed to be one of the main aims for therapeutic cancer management centred on the finding that PI3K signalling hyperactivity associated with the growth of human tumour and cancer cell invasive potential [14]. Research has shown that activation of PI3K pathway serves as an adaptive resistance mechanism to CDK4/6 inhibition, which leads to an increased phosphorylation of AKT and CDK2 activation, providing evidence for testing PI3K pathway inhibitors to overwhelmed resistance to

CDK4/6 inhibitor [16]. Several inhibitors of PI3K have been developed and categorized for each isoform according to their specificity, divided into (1) pan-inhibitors of PI3K, targeting various class I isoforms (α, β, δ and γ) of PI3K, (2) isoform-selective PI3K inhibitors and (3) dual PI3K/mTOR inhibitors. Table 1 revealed the drugs intended for PI3K in clinical trials. PI3K signalling pathway inhibitors have common toxicity profiles that include rash, gastrointestinal disturbances, hyperglycaemia, alopecia, liver enzyme elevation and fatigue.

1.3.1 Pan-PI3K inhibitor

Pan-inhibitors of PI3K are the first to come into clinical practice and are known as the first generation inhibitors. They specifically inhibit kinase activity of p110 by acting as mimetics of ATP, reversibly binding and competitively to the ATP-binding pocket of p110. BKM120 (buparlisib) is the most advanced and thoroughly studied pan-inhibitors of PI3K in clinical research and is widely assessed in hormone positive cancer of the breast, regularly in amalgamation with endocrine therapy. Other pan-class I inhibitors of PI3K in clinical trials comprise GDC-0941, XL147, PX-866 and CH5132799. Buparlisib displays an excellent oral bioavailability and important antitumor activity in in-vivo at tolerated doses in human tumour xenograft models. Studies have shown that buparlisib was tested in patient with breast cancer in combination with chemotherapy in phase II/III clinical research [17].

1.3.2 Isoform-specific PI3K inhibitors

Second generation inhibitors, known as isoform-selective PI3K inhibitors, are primarily cancer mutated and their selective inhibition have been expressed to obstruct PI3K signalling in reaction to diverse stimuli of growth factors [17]. Isoform-specific PI3K inhibitors were designed to address particular PI3K pathway alterations, whilst preventing the combined toxicity of numerous isoform inhibitors. Different PI3K isoforms selective inhibition requires therapeutic doses of drugs without toxicity off-target, requiring a lesser range of patients. Novel isoform-specific PI3K inhibitors have created much interest because of the hypothesized benefit so as to have less toxicity compared to pan-class I inhibitors, allowing these agents to be tolerated at doses that can result to a more absolute kinase activity inhibition.

Studies have shown attention in the development of inhibitors of PI3Kα (BYL719 and MLN1117) in cancers with mutations of PIK3CA and PI3Kβ inhibitors (AZD8186, GSK2636771 and SAR260301) in PTEN loss tumours. An oral selective PI3Kα isoform inhibitor BYL719 (Alpelisib), is the first oral PI3Ki to specifically aim the class I p110α isoform (IC_{50}= 4.6 nM) and was tested as a single agent showing dose-dependent antitumor activity in xenograft tumour model [2].

1.3.3 Dual PI3 K/mTOR inhibitor

PI3K and mTOR fit into PI3K-related kinases (PIKK) superfamily, share structural domains and as a result, some inhibitory compounds aim both kinases, they are known as the third generation inhibitors. The progress of dual PI3K/mTOR inhibitors was focused on established structural connections amongst the p110 ATP-binding domain and the catalytic domain of mTOR. These agents are active site of mTOR inhibitors that have the benefit of inhibiting mTOR kinase activity regardless of whether it is in TORC1 or TORC2 complex. PI3K and mTOR dual inhibitors aim both holoenzymes active sites, thereby inhibiting the upstream and downstream AKT pathway. These dual inhibitors have a wider cancer activity where PI3K/AKT is not the primary driver of mTOR activity. Dual PI3K/mTOR in clinical research includes BEZ235, XL765 and PF04691502 [18].

Relative to other oncogenic kinases, inhibitors of PI3K have demonstrated only limited efficiency in patients to date [19]. Some clinical research has shown that treatment involving inhibitors of PI3K leads to controlled activation of the estrogen pathway. Research has also shown that inhibition of PI3K has augmented DNA damage and caused resistance of drugs in a genetically modified mouse model of cancer of the breast [18].

2. PI3K INHIBITORS IN CANCER AND COMBINATION OF THERAPEUTICS APPROACHES IN CANCER

With PI3K's principal function in breast cancer, inhibition of this pathway's extreme activation is a favourable strategy for treatment of cancer. Resistance of PI3K inhibitors can be treated in some cases with combination therapy that includes other scientifically proven agents. PI3K and ER signalling mediates reciprocal antagonism in ER positive breast cancer, resulting in pharmacological inhibition of one pathway encouraging improved signalling via the other. Previously, inhibition of PI3K stimulated ER-dependent transcription; recent study has given insights into this occurrence by showing that PI3K inhibition stimulates activation of lysine methyltransferase, which acts as ER-dependent transcription enhancer [20]. Despite the proven correlation amongst PI3K pathway and breast cancer progression, inhibitors of PI3K have not attained

hopeful therapeutic efficiency in clinical studies. Equated with drugs aiming other oncogenic kinases, inhibitors of PI3K have revealed to date only modest efficacy in patients [19]. Some clinical trials showed that breast cancer treatment with inhibitors of PI3K leads to controlled activation of estrogen pathway. Other research found that inhibition of PI3K increase damage to the DNA and induced resistance to drugs in a genetically modified breast cancer mouse model. These data indicate that the appropriate mixture of inhibitors of PI3K with other therapeutic materials overcomes resistance to optimize therapeutic results (Table 2).

2.1 PI3K and RTK Inhibitors

Numerous studies have demonstrated that inhibition of PI3K pathway induces multiple RTKs, such as HER2, to be expressed and phosphorylated through the fork head box O-regulated transcriptional development in cancer of the breast cells. Preclinical studies showed that combining neutralizing antibody of HER3 and selective inhibitor p110α significantly lessen development of cancer of the breast xenografts. Research has shown the efficacy of combining inhibitor of PI3K and dual EGFR and inhibitor of HER3 to circumvent this resistance mechanism [21].

Table 1. Drugs targeting PI3K in clinical trial [6]

Compound	Terminated	Phase I	Phase II	Phase III	FDA approved
Dual PI3K/ mTOR inhibitor	BGT-226 (Novartis) DS-7423 (Dailchi Sankyo)	GSK458/ Omipalisb (GlaxoSmit-hKline)	BEZ235/Dactolisi (Novartis) LY3023414 (Eli Lilly)	PF-05212384/ gedatolisib/PKI-587 (Pfizer)	
Pan-PI3K inhibitor	GDC-0941/Pictilsib (Genentech) PX-866 (Oncothyreon)	CH5132799 (TohokuNiproPharm)	XL147/Pilaralisib (Sanofi) ZSTK474 (Zenyaku Kogyo)	BKM-120/Buparlisib (Novartis)	BAY80-6946/ Copanilsib (Bayer)
Isoform-specific PI3K inhibitor	AZD8835 (AstraZeneca)	AZD8186 (AstraZeneca)β/δ KA2237 (Karus Therapeutics)	AMG319 (Amgen) δ Umbrailsib/ TGR-1202 (TC Therapeutics)δ	GDC-0032/Taselisib (Genentech) α/δ/γ BYL719/Alpelisib (Novartis)α	Duvelisib/ IPI-145 (Infinity)δ/ γ

Table 2. Schematic description of the PI3K inhibitors in breast cancer with other therapies [11]

Combination Therapeutic Approaches	Applied Drugs	Type of Study	Type of Breast Cancer	Reference
RTK and PI3K Inhibitors	PI3K inhibitor (buparl-isib) & inhibitor of HER2 (lapatinib)	Phase IB trial	HER2-positive advanced breast cancer	[11]
	PI3K inhibitor (BKM120/buparlisib) &HER2 Inhibitor(trastuzumab)	Phase II trial	HER2-positive locally advanced breast cancer	[18]
Endocrine Therapy and PI3K Inhitors	PI3K inhibitor(buparl-isib) & ER antagonist (fulvestrant)	Randomized double blind placebo controlled phase III trial	HER2-negative Advanced breast cancer	[21]
	PI3K inhibitor(buparl-isib) & ER antagonist (fulvestrant)	Randomized dou-ble blind placebo-controlled phase III trial	HER2-negative Advanced breast cancer progression	[16]
PI3K and PARR Inhibitors	PI3K inhibitor (BKM120) & PARP Inhibitor (Olaparib)	Phase I trial	High-grade breast cancer	[17]




Fig. 1. Flow chart showing PI3K Pathway [20]




Fig. 2. Summary of cell signalling facilitated by the tyrosine kinase receptors (RTKs) Her2/Neu and estrogen receptors (ERs), two main components of cancer of the breast development. Activation of these receptors triggers the PI3K pathway, promoting cell growth, proliferation, survival and other cancer hallmarks [29]




Fig. 3. PI3K pathway inhibitors in cancer. Promoters and suppressors of tumours are labelled in orange and green respectively. Receptor tyrosine kinase (RTK); G-protein-coupled receptor (GPCR); phosphatidylinositol 3-kinase (PI3K); phosphatidylinositol 4,5-bisphosphate (PIP2); phosphatidylinositol 3,4,5-triphosphate (PIP3); phosphoinositide dependent kinase-1 (PDK1); inositol polyphosphate 4-phosphatase type II (INPP4B); mammalian target of rapamycin complex (mTORC); phosphatase an tensin homolog (PTEN); 4E-binding protein 1(4EBP1); S6 kinase (SK6) [26]

2.2 PI3K Inhibitors and Endocrine Therapy

Estrogen receptor (ER) signals pathway cross-talks with other pathways signposted by peptide growth factor. Combining hormonal agents with selective agents may increase effectiveness and can delay the development of endocrine resistance. PI3K pathway directly and indirectly controls ER pathway. Preclinical results also confirmed that there is crosstalk between the PI3K and the ER signalling pathway. Studies using breast carcinoma cell lines have shown an association between Akt signalling pathway activity and endocrine resistance [9]. Preclinical study suggested that the removal of PI3K in ER/PIK3CA model resulted in transcription activation of ER-dependent, comprising the ER promoter and ER-binding sites genes in the coding sequence. Additional research has shown that decreased levels of PTEN have contributed to ER-positive breast cancer endocrine resistance that may be resolved by combining inhibitor of PI3K with endocrine therapy. Thus, joint PI3K inhibition and ER could be an important breast cancer technique and there are many clinical trials underway [22].

2.3 PI3K and Poly-ADP-Ribose Polymerase Inhibitors

Dual research presented foremost verification that inhibitor of PI3K induce DNA homologous recombination deficiency in BRCA-like triple-negative cancer of the breast, with increased poly-ADP-ribosylation as well as decreased BRCA1/2 regulation [23]. The writers also demonstrated that

application of inhibitor of poly-ADP-ribose polymerase (PARP) to inhibitors of PI3K significantly decreased tumour growth in triple negative cancer of the breast with wild-type BRCA1.

2.4 Importance of PI3K in Breast Cancer and Current Clinical Practice

PI3K is a cell signalling pathway involving development, multiplying, motility, survival, immune response regulation and metabolism [7]. Changes to PI3K pathway has been observed in nearly all human tumours, comprising cancer of the breast around 60% of the tumours pose diverse variations which hyperactivate this pathway. The abnormal regulation of this pathway was associated with a broad range of cancer characteristics, including unregulated genomic uncertainty, proliferation and metabolic reprogramming in tumour cells [10]. Activity of the PI3K pathway is one of the key reasons of cancer cell resistance to antitumor therapies. A latest study has shown that silenced PI3Kβ cancer of the breast cells have less metastasis of the lungs by controlling extravasations that can be linked with distracting tumour cell invasion triggered by macrophage [24].

There are specific clinical reasons for the use of PI3K inhibitors, primarily due to the effects of this signalling mechanism in a wide variety of diseases. Present clinical first line endocrine therapy for HR positive/ HER2 negative breast cancer patients consists of the administration of a CDK4/6 inhibitor, palbociclib or ribociclib aromatic inhibitor based on the findings of clinical phase III studies [25]. There is indication of a crosstalk amongst the CDK4/6 and PI3K pathways. Goel et al 2018 further demonstrated that inhibition of CDK4/6 does not just inhibit retinoblastoma (Rb) phosphorylation but as well decrease phosphorylation of TSC2, thus moderately impending mTORC1 activities [26]. Resistance to CDK4/6 inhibitors has been shown to be based on the activation of non-canonical PI3K compensatory cyclin D1-CDK2 pathway, resulting to Rb phosphorylation. The combination of PI3K and CDK4/6 treatment inhibitors will overwhelm single-agent CDK4/6i resistance due to the down-regulation of cyclin D1 [27]. Combination of endocrine therapy, inhibition of CDK4/6 and PI3K inhibition has been shown to be more efficient in inducing regression of tumours. The earliest to show a clinically important result of inhibition of PI3Kα in tumours with mutations of PIK3CA is the phase III SOLAR-1 trial [28].

3. CONCLUSION

One of the frequently altered signalling pathways in human cancers is PI3K; it can be regulated by the tyrosine kinase receptor or by alterations in some of its main components. PI3K signalling contributes to cancer of the breast growth. The high occurrence of genetic changes in this pathway gives the basis for the improvement of PI3K aiming inhibitors. There are several PI3K inhibitors which can be either Pan-PI3K, dual or isoform-specific, some of which are presently being clinical studied. In breast cancer, these inhibitors may be effective in tumours that are receptor-positive to estrogen, HER2-overexpressive, PIK3CA-mutated tumours or PTEN loss. While p110α is frequently mutated in breast tumours, interesting targets are now emerging for other class IA PI3Ks especially p110β.

Clinical studies using inhibitors of PI3K as a monotherapy have demonstrated minimal clinical success, likely as a result of PI3K inhibition resistance and deprived acceptability of inhibitors of PI3K. pan-PI3K and inhibitors of Dual PI3K/mTOR found their means into clinical trials as monotherapy with little success. Different PI3K isoforms, in particular tumour types, play non-redundant functions, isoform-specific PI3K inhibitors show enhanced specificity and reduction in toxicity over pan-PI3K inhibitors and dual PI3K/mTOR.

The PI3K is one of the frequently abnormal pathways in cancer and is presently an essential emphasis for the improvement of anticancer drugs. As cancer medicine shifts towards an increasingly personalized model, inhibitors of PI3K pathway are possible to be a vital aspect of many cancers' therapeutic strategy. Inhibition of PI3K in cancer of the breast cells as a therapeutic target showed comparatively reasonable efficacy in clinical trials as a monotherapy. To validate these approaches, numerous PI3K inhibitors combination with other active drugs substantially exploited therapeutic results as well as other clinical trials are on-going. Inhibiting PI3K isoforms that reinstate the immune response to the anti-tumour as well as enhance response to checkpoint obstruction of treatment that may be a promising aim for cancer of the breast immunotherapy is important. To confirm these findings, these therapeutic concepts ought to be followed along with clinical trials. Chemotherapy, hormones, biological agents and radiation are performed in combination therapy trials. Finally, with a lot of reason for hope, the culmination of several years of research investigating the importance of PI3K pathway inhibition is finally coming to fruition.

Several studies have shown that inhibitors of PI3K have been more efficient in PI3K mutation patients, also certain patients lacking known PI3K mutations have profited from PI3K inhibitors and certain patients with PIK3CA or other mutations have had no advantage. It is essential to define accurate biomarkers that can guide patient selection and decide which tumor type and genetic summary can benefit from PI3K inhibition. Inhibition of PI3K is undergoing investigation as a possible approach for developing novel cancer treatment therapies. Clinical development of PI3K inhibitors is in motion, and remains difficult to optimize the effectiveness of such agents in treating patients. Understanding the specific mechanism of PI3K signalling and PI3K inhibition will be important, refining patient selection methods and combination approaches can further improve the efficiency of such agents in action. Continued research is importance to explain the function of PI3K in cancer of the breast.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. World Health Organization. International Agency for Research on Cancer; Latestglobal Cancer Data; 2018.
2. Alabi MA, Muthusamy A, Kabekkodu SP, Adebawo OO, Satyamoorthy K, Ajagun EJ. In vitro cytotoxicity of recipes derived from Nigerian medicinal plants (NMPs) on breast cancer. Int Chem Sci. 2017;90-97.
3. Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2016;66:7e30.
4. Aizawa K, Liu C, Tang S. Tobacco carcinogen induces both lung cancer and non-alcoholic steatohepatitis and hepatocellular carcinomas in ferrets which can be attenuated by lycopene supplementation. International Journal of Cancer. 2016;139.
5. Elbachiri M, Fatima S, Bouchbika Z. Breast cancer in men: about 40 cases and literature review. Pan African Medical Journal. 2017; 28:287.
6. Yang J, Nie, J, Ma X, Wei Y, Peng Y, Wei X. Targeting PI3K in cancer: mechanisms and advances in clinical trials. Molecular Cancer. 2019;18(1):26.
7. Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. The PI3K pathway in human disease. Cell. 2017;170(4);605-635.
8. Asati V, Mahapatra DK, Bharti SK. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives. Eur J Med Chem. 2016;109:314-341.
9. Ortega MA, As´unsolo A, Leal J. Implication of the PI3K/Akt/mTOR pathway in the process of incompetent valves in patients with chronic venous insufficiency and the relationship with aging. Oxidative Medicine and Cellular Longevity. 2018;14.
10. Lien EC, Dibble CC, Toker A. PI3K signaling in cancer: beyond AKT. Current Opinion in Cell Biology. 2017;45:62-71.
11. Sai J, Owens P, Novitskiy SV, Hawkins OE, Vilgelm AE, Yang J, Sobolik T, Lavender N, Johnson AC, McClain C, Ayers GD, Kelley MC, Sanders M, Mayer IA, Moses HL, Boothby M, Richmond A. PI3K inhibition reduces mammary tumor growth and facilitates antitumor immunity and anti-PD1 responses. Clinical Cancer Research. 2017;23(13):3371–3384.
12. She QB, Gruvberger-Saal SK, Maurer M, Chen Y, Jumppanen M, Su T, Dendy M, Lau YK, Memeo L, Horlings HM, van de Vijver MJ, Isola J, Hibshoosh H, Rosen N, Parsons R, Saal LH. Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer. BMC Cancer. 2016;16(1):587.
13. Triscott J, Rubin MA. Prostate Power Play: Does Pik3ca Accelerate Pten- Deficient Cancer Progression? Cancer Discov. 2018;8: 682–5.
14. Croessmann S, Sheehan JH, Lee KM, Sliwoski G, He J, Nagy R, Riddle D, Mayer IA, Balko JM, Lanman R. PIK3CA C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3Kalpha Inhibitors. Clin Cancer Res. 2018;24:1426-1435.
15. Keegan NM, Gleeson JP, Hennessy BT, Morris PG. PI3K inhibition to overcome endocrine resistance in breast cancer,". Expert Opinion on Investigational Drugs. 2018;27(1):1–15.
16. Zhang J, Xu K, Liu P, Geng Y,Wang B, Gan W. Inhibition of Rb phosphorylation leads to mTORC2-mediated activation of Akt. Mol Cell. 2016;62(6):929–42.
17. Martın M, Chan A, Dirix L. A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4). Ann Oncol. 2017;28(2):313–320.

18. Ardestani A, Lupse B, Kido Y, Leibowitz G, Maedler K. mTORC1 signaling a double-edged sword in diabetic cells. 2018;27(2):314-331.
19. Okkenhaug K, Graupera M, Vanhaesebroeck B. Targeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis, and immunotherapy. Cancer Discovery. 2016; 6(10):1090–1105.
20. Toska E, Osmanbeyoglu HU, Castel P, Chan C, Hendrickson RC, Elkabets M, Dickler MN, Scaltriti M, Leslie CS, Armstrong SA, Baselga J. PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D. Science. 2017; 355:1324–1330.
21. Rimawi MF, De Angelis C, Contreras A, Pareja F, Geyer FC, Burke KA, Herrera S, Wang T, Mayer IA, Forero A, Nanda R, Goetz MP, Chang JC, Krop IE, Wolff AC, Pavlick AC, Fuqua SAW, Gutierrez C, Hilsenbeck SG, Li MM, Weigelt B, Reis-Filho JS, Kent Osborne C. Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. Breast Cancer Research and Treatment. 2018;167(3):731–740.
22. Juric D, Rodon J, Tabernero J, Janku F, Burris HA, Schellens JHM, Middleton MR, Berlin J, Schuler M, Gil-Martin M, Rugo HS, Seggewiss-Bernhardt R, Huang A, Bootle D, Demanse D, Blumenstein L, Coughlin C, Quadt C, Baselga J. Phosphatidylinositol 3-kinase a-selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors: results from the first-in-human study. Journal of Clinical Oncology. 2018;36(13):1291–1299. DOI: 10.1200/JCO.2017.72.7107.
23. Condorelli R, Andre F. Combining PI3K and PARP inhibitors for breast and ovarian cancer treatment. Annals of Oncology. 2017;28(6): 1167-1168.
24. Khalil BD, Hsueh C, Cao Y, Abi Saab WF,Wang Y, Condeelis JS, Bresnick AR, Backer JM. GPCR signaling mediates tumor metastasis via PI3Kb. Cancer Research. 2016;76(10):2944–2953. DOI: 10.1158/0008-5472.
25. Im SA, Lu YS, Bardia A. overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019;381(4):307.
26. Goel S, DeCristo MJ, McAllister SS, Zhao JJ. CDK4/6 inhibition in cancer: beyond cell cycle arrest. Trends Cell Biol. 2018;35(32): 911-925.
27. Herrera-Abreu M, Palafox M, Asghar U. Early adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptorpositive breast cancer. Cancer Res. 2016;76(8):230113.
28. André F, Ciruelos EM, Rubovszky G, Campone M, Loibl S, Rugo HS. LBA3_PRAlpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Results of the phase III SOLAR-1 trial. Ann Oncol. 2018;29(suppl_8): mdy424.010-mdy424.010.
29. Guerin M, Rezai K, Isambert N, Campone M, Autret A, Pakradouni J, Provansal M, Camerlo J, Sabatier R, Bertucci F, Charafe-Jauffret E, Hervieu A, Extra JM, Viens P, Lokiec F, Boher JM, Goncalves A. PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer. European Journal of Cancer. 2017;86:28-36.

© Copyright International Knowledge Press. All rights reserved.

View publication stats